Funding for this research was provided by:
ReumaNederland (LLP10 (Longstanding Research Support))
Received: 14 August 2020
Accepted: 5 March 2021
First Online: 22 March 2021
: This study did not fall under the scope of the Medical Research Involving Human Subjects Act, as declared by the locally appointed ethics committee of the University Medical Center Utrecht (reference no. 16-361C).
: Not Applicable.
: VSM is CEO and founder of MyOwnMed, Inc. and has received speaker and/or consulting fees from Conopco Inc. (Unilever), Janssen Research and Development LLC, Kintai Therapeutics Inc., Novartis Pharma AG, Otsuka America Pharmaceutical Inc., and Sanofi US. The other authors have indicated they have no potential conflicts of interest to disclose.